Clinical Trials Logo

Filter by:
NCT ID: NCT00552643 Recruiting - Wounds and Injuries Clinical Trials

Study to Evaluate Polyheal-1 in Treatment of Recalcitrant Wounds

Start date: May 2008
Phase: N/A
Study type: Interventional

The objective of this study is to evaluate the performance of Polyheal-1 compared to Saline in the treatment of recalcitrant wounds including venous, post-operative and post-traumatic chronic wounds with different etiologies including wounds with exposed bone and/or tendons.

NCT ID: NCT00552344 Completed - Crohn Disease Clinical Trials

A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease

Start date: May 2008
Phase: Phase 3
Study type: Interventional

The primary objective of the study is to assess the safety of long term therapy with Certolizumab Pegol in those subjects participating in study C87085 [NCT00552058].

NCT ID: NCT00552266 Recruiting - ADHD Clinical Trials

Methylphenidate in ADHD With Trichotillomania

Start date: October 2007
Phase: Phase 4
Study type: Interventional

This study will evaluate the safety and effectiveness of methylphenidate in treating attention deficit hyperactivity disorder (ADHD) in children with both ADHD and trichotillomania. Trichotillomania is an impulse control disorder. There is growing evidences of the involvement of dopaminergic neurotransmission in the pathophysiology of trichotillomania. Reported increase in the prevalence of ADHD among patients with impulse control disorders, such as pathological gambling as well as trichotillomania, may result from the overlapping pathophisiological background. It is hypothesized that in cases of ADHD comorbid with trichotillomania methtylphenidate treatment will exhibit beneficial effects in both the ADHD and the hair pulling.

NCT ID: NCT00552162 Completed - Appendicitis Clinical Trials

NOTES Transvaginal Cholecystectomy and Appendectomy

Start date: June 2008
Phase: N/A
Study type: Interventional

Natural Orifice Translumenal Endoscopic Surgery (NOTES) is considered by many leading expert surgeons to be the next step in MIS (Minimally Invasive Surgery). This is a rapidly evolving area of preclinical research and several groups worldwide are developing this surgical approach together with industry support. In this new surgical technique, abdominal operations are performed using the oropharynx, rectum, or vagina as the ports of entry to the peritoneal cavity instead of incisions on the abdominal wall. NOTES offers all the advantages of minimally invasive surgery (MIS) and also completely eliminates trauma to the abdominal wall and the numerous complications of abdominal wall incisions. A NOTES procedure eliminates any visible scar and could also potentially reduce post operative pain due to the elimination of abdominal wall trauma. In this trial we intend to operate healthy women who need to undergo cholecystectomy or appendectomy. The operations will be performed through the vagina as the access port to the peritoneum and it will be monitored with laparoscopic vision for safety reasons.

NCT ID: NCT00552058 Completed - Crohn Disease Clinical Trials

Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Remission in Patients With Crohn's Disease

Start date: March 2008
Phase: Phase 3
Study type: Interventional

The primary objective of the study is to evaluate efficacy of certolizumab pegol in inducing clinical remission in patients with moderate to severe Crohn's disease as compared with placebo based on Crohn's Disease Activity Index (CDAI) score at Week 6.

NCT ID: NCT00551382 Recruiting - Clinical trials for Upper Respiratory Tract Infection

Montelukast as Prophylaxis for Upper Respiratory Tract Infections in Children: a Randomised, Double-blind, Placebo-controlled Study

Start date: November 2007
Phase: Phase 3
Study type: Interventional

Viral upper respiratory tract infection (URI) is one of the most common diseases among toddlers and pre-school children.Complete and effective prevention measures for URI are currently unavailable. Montelukast (Singulair ) is a selective leukotriene-receptor antagonist that inhibits the cysteinyl leukotriene 1 receptor. It is well tolerated and safe even in young children. Montelukast is an effective treatment for asthma (and allergic rhinitis from 1 year of age. Infections with viruses causing URI such as Influenza A, Rhinovirus and respiratory syncitial virus increases leukotriens levels in nasal secretions. Therefore, one may postulate that leukotriens inhibitors may reduce symptoms during URI. However the effect of montelukast as a treatment for non-specific cough was not properly studied and there are no studies on the effect of montelukast as prevention for URI. Hypothesis: Prophylactic treatment with Montelukast will reduce the incidence and severity of upper respiratory infection in children.

NCT ID: NCT00551226 Not yet recruiting - Tuberculosis Clinical Trials

Follow up of Autoantibodies in Active Tuberculosis

Start date: November 2007
Phase: N/A
Study type: Observational

We have previoulsy shown that patients with active Tuberculosis develop a wide array of autoantibodies including rheumatoid factor, anti-CCP, Antinuclear facyor and anti Sm antibodies. The purpose of this study is to evaluate whether the level of autoantibodies decrease after treatment aganist tuberculosis.

NCT ID: NCT00550706 Completed - Cancer Clinical Trials

Drug Utilization Prevalence in a Pediatric Care Medical Center

Start date: October 2007
Phase: N/A
Study type: Observational

One year prospective analysis of drug utilization and prescription point prevalence of medications in a pediatric tertiary care university medical center. Off-label use of medications in the study population will be also registered.

NCT ID: NCT00550576 Completed - Bipolar Disorder Clinical Trials

Antibodies to Digoxin for Bipolar Disorder

Start date: October 2007
Phase: Phase 2
Study type: Interventional

Subjects suffering from bipolar disorders treated with specific medications will give their informed concent and will receive intravenously only one dose of Digoxin antibodies (Fab). Their response to this therapy will be measured accordingly.Previous medications will be not changed A base line serum Endogenous Digitalis-like Compounds (DLC)levels will be measured using a specific laboratory technique and these compounds will be measured at 6 and 24 hours after Fab therapy. Patients also will be followed using clinical and psychological tests

NCT ID: NCT00550069 Not yet recruiting - Hypoglycemia Clinical Trials

Observational Study of Infants Born at 34 to 37 Weeks of Gestation Until the Age of 1 Year

Start date: December 2007
Phase: N/A
Study type: Observational

Late preterm infants are at an increased risk for short and long term morbidity (during the 1st year of life, their neurodevelopmental status may also be delayed as compared to infants born at term). The term "near term infants" is probably a deceiving one.